A lung disorder that is mainly associated with chronic allograft dysfunction after lung transplantation and that is characterized by inflammation and fibrosis of bronchiolar walls that reduce the diam...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Documentation on bronchiolitis obliterans syndrome is limited due to its rarity and the complexity of its clinical presentation, which often overlaps with other pulmonary conditions. The condition primarily affects individuals post-lung transplantation, making systematic studies challenging. As a result, comprehensive clinical characterization and phenotype documentation are ongoing.
To navigate bronchiolitis obliterans syndrome, it is crucial to consult with a pulmonologist who specializes in post-transplant lung care. Engaging with a transplant center that has experience in managing BOS can provide tailored treatment options. While no specific patient organizations are currently identified, resources like GARD (rarediseases.info.nih.gov) can offer valuable information. Additionally, inquire about participating in clinical trials, which may provide access to emerging therapies.
There are several orphan drugs in development for bronchiolitis obliterans syndrome, including interleukin-1 receptor antagonist (IL-1Ra), liposomal cyclosporine, and recombinant human club cell protein. Currently, there are 163 active clinical trials exploring various aspects of this condition. For more information, you can search for ongoing trials at ClinicalTrials.gov using this link: https://clinicaltrials.gov/search?cond=bronchiolitis%20obliterans%20syndrome.
Actionable guidance for navigating care for bronchiolitis obliterans syndrome
To navigate bronchiolitis obliterans syndrome, it is crucial to consult with a pulmonologist who specializes in post-transplant lung care. Engaging with a transplant center that has experience in managing BOS can provide tailored treatment options. While no specific patient organizations are currently identified, resources like GARD (rarediseases.info.nih.gov) can offer valuable information. Additionally, inquire about participating in clinical trials, which may provide access to emerging therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 4 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.